Announcement PDF Imagion Biosystems Limited ASX: IBX Imagion Biosystems Limited ASX: IBX ACN 616 305 027 Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 imagionbiosystems.com | investor@imagionbio.com A S X A N N O U N C E M E N T | 1 S e p t e m b e r 2 0 2 6 Cleansing Notice – Issue of Shares Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, lodges the following cleansing notice for the new ordinary shares: Section 708A Cleansing Notice The Company gives notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that: (a) it issued 40,208,334 IBX Listed Options expiring 13 December 2027 (Options), 2,708,334 Options on 27 August 2026 to participants in the placement announced 25 June 2026 and 37,500,000 on 31 August 2026 to the lead manager, or their nominees, of the Placement; (b) the Options were issued without disclosure to investors under Part 6D.2 of the Corporations Act; (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act; (d) as at the date of this notice the Company has complied with: i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and ii. sections 674 and 674A of the Corporations Act; and (e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed pursuant to section 708A(6)(e). Authorisation & Additional Information This announcement was authorised by the Board of Imagion Biosystems Limited. Join Imagion Biosystems’ Investor Hub Stay up to date on news and announcements or interact with our team through questions and comments via Investor Hub. Register at investor.imagionbiosystems.com. About Imagion Biosystems Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its- Imagion Biosystems Limited ASX: IBX Imagion Biosystems Limited ASX: IBX ACN 616 305 027 Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 imagionbiosystems.com | investor@imagionbio.com class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com. Executive Chairman Contact Details Bob Proulx investor@imagionbio.com AU: +61 3 9692 7222 Media Enquiries & Investor Relations Erich Boileau, Boileau & Co. imagionbio@boileau.co US : +1 (616) 786-4461